Philips stock faces EUR 288 million Respironics settlement

Philips is moving toward a settlement of long-running US investigations linked to its recalled Respironics sleep and respiratory devices. The company disclosed the agreement in principle with the US Department of Justice on Tuesday, November 3, while MedTech Dive reported the proposed resolution on November 4.

The agreement covers criminal and civil investigations related to the recall. Philips recorded a EUR 288 million provision for the proposed settlement, with payment expected in the first quarter of 2027. The agreement still requires final documentation, so the disclosure does not represent a completed payment or a fully executed settlement.

MedTech Dive reported that the recall involved more than 15 million devices, including continuous positive airway pressure and bilevel positive airway pressure machines as well as ventilators. The issue concerned soundproofing foam that could break down into particles and be inhaled by users.

Legal relief remains incomplete

The proposed payment would address the US Department of Justice investigations, but it does not remove every Respironics-related risk. MedTech Dive reported that the settlement is separate from a 2024 US Food and Drug Administration consent decree that restricts the sale of certain respiratory devices until Philips meets the agency's requirements.

Chief Executive Roy Jakobs said Philips was working toward a return to the US market for affected products, but that the timing ultimately depended on the FDA. The company is therefore continuing to prepare for a possible market return without controlling the authorization timetable.

The proposed settlement also excludes other proceedings, including an investigation by US state attorneys general. For investors, that distinction matters: the agreement can reduce one part of the legal overhang, but it does not establish that all recall-related liabilities have been resolved.

Shares trade above prior Xetra close

Philips stock traded at 27.37 euros on Lang & Schwarz at 11:08 CET on Friday, November 13, 0.44 percent above the Xetra close of Thursday, November 12. The comparison places the shares modestly higher during the session, without establishing that the move was caused by the settlement news.

The market focus is likely to remain on the timing and final terms of the Department of Justice agreement, the payment in early 2027 and the unresolved state-level proceedings. The FDA's decision on the return of affected Respironics products is another relevant milestone for the division.

European healthcare shares trade against a broader market backdrop reflected by the AEX Index.

More news and analyses on Philips stock.